文献速递心律失常

阿贝拉西单抗在房颤伴不同肾功能患者中的安全性:AZALEA-TIMI 71预设分析

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

AZALEA-TIMI 71随机试验的预设二次分析,比较阿贝拉西单抗与利伐沙班在房颤患者不同肾功能亚组中的出血安全性。共纳入1284例患者,结果显示阿贝拉西单抗较利伐沙班降低大出血或临床相关非大出血风险,且与肌酐清除率无关,在肾功能不全患者中绝对风险降低更明显。

要点

  • 肌酐清除率≤50 mL/min者使用利伐沙班即使减量,出血发生率仍高于>50 mL/min者(13.6 vs 7.0/100人年)。
  • 阿贝拉西单抗在肌酐清除率≤50 mL/min者中绝对风险降低10.1/100人年,>50 mL/min者为4.2/100人年。

核心结论

  • 在AZALEA-TIMI 71的二次分析中,阿贝拉西单抗较利伐沙班一致降低出血风险,不受肾功能影响。
  • 阿贝拉西单抗可能在慢性肾脏病患者中具有更有利的安全性特征,但需更大规模研究验证其房颤卒中预防疗效。

研究设计与样本

  • AZALEA-TIMI 71随机临床试验的预设二次分析,按随机化时肌酐清除率分层。
  • 共纳入1284例房颤患者,中位年龄74岁,44.5%为女性,中位肌酐清除率71 mL/min,20.6%患者肌酐清除率≤50 mL/min。
  • 患者随机接受阿贝拉西单抗150 mg或90 mg每月一次,或利伐沙班(肌酐清除率>50 mL/min者20 mg每日,≤50 mL/min者15 mg每日)。
  • 排除肌酐清除率<15 mL/min或透析患者。

主要发现

  • 利伐沙班组中,肌酐清除率≤50 mL/min者大出血或临床相关非大出血发生率高于>50 mL/min者(13.6 vs 7.0/100人年),尽管已减量。
  • 单独大出血及包含大出血、临床相关非大出血和轻微出血的复合终点结果一致。
  • 分别比较阿贝拉西单抗两个剂量与利伐沙班,结果相似。

临床怎么用

  • 对于房颤合并肾功能不全患者,阿贝拉西单抗可能提供不依赖肌酐清除率的出血风险降低。
  • 利伐沙班在肌酐清除率≤50 mL/min者中即使减量,出血风险仍较高,需密切监测。

局限性

  • 本研究为二次分析,阿贝拉西单抗预防房颤卒中的疗效需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with higher rates of bleeding with anticoagulation. In the AZALEA-TIMI 71 randomized clinical trial, abelacimab, a novel factor XI inhibitor, reduced rates of major or clinically relevant nonmajor (CRNM) bleeding compared with rivaroxaban in patients with AF. OBJECTIVE: To examine the safety of abelacimab vs rivaroxaban across a range of kidney function. DESIGN, SETTING, AND PARTICIPANTS: The AZALEA-TIMI 71 study randomized patients with AF to 1 of 2 abelacimab doses (150 mg or 90 mg monthly) or to rivaroxaban, with stratification by creatinine clearance (CrCl). Patients with CrCl less than 15 mL/min or receiving dialysis were excluded. This secondary analysis of AZALEA-TIMI 71 examines outcomes by randomized treatment and CrCl at randomization. INTERVENTION: Patients randomized to rivaroxaban with a CrCl greater than 50 mL/min received rivaroxaban, 20 mg, daily, and those with a CrCl of 50 mL/min or less received rivaroxaban, 15 mg, daily. Patients randomized to abelacimab received the assigned dose irrespective of CrCl. MAIN OUTCOMES AND MEASURE: The primary outcome was major bleeding or CRNM bleeding. RESULTS: Among 1284 patients, median (IQR) age was 74 (69-78) years and 572 patients (44.5%) were female. Median (IQR) CrCl was 71 (54-90) mL/min, with 264 patients (20.6%) having a CrCl of 50 mL/min or less. In the rivaroxaban group, patients with CrCl of 50 mL/min or less experienced higher rates of major or CRNM bleeding compared with those with CrCl greater than 50 mL/min despite dose reduction (incidence rates, 13.6 vs 7.0 per 100 person-years). Abelacimab reduced major or CRNM bleeding vs rivaroxaban irrespective of CrCl (CrCl ≤50 mL/min: hazard ratio [HR], 0.26; 95% CI, 0.12-0.54; >50 mL/min: HR, 0.40; 95% CI, 0.26-0.62; P value for interaction = .33), with absolute risk reductions of 10.1 vs 4.2 per 100 person-years in those with CrCl of 50 mL/min or less vs greater than 50 mL/min, respectively (P value for interaction = .09). This risk reduction was consistent for major bleeding alone and for a broader composite inclusive of major, CRNM, and minor bleeding. Results were similar when comparing the individual abelacimab doses to rivaroxaban. CONCLUSIONS AND RELEVANCE: In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in AF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Patel, Giugliano, Morrow, et al. Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40888686. doi:10.1001/jamacardio.2025.3393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。